TWIST BIOSCIENCE Business Summary

Twist Bioscience Corporation (TWST) operates a disruptive synthetic biology business model centered on its proprietary semiconductor-based DNA synthesis platform, which replaces traditional plastic plates with silicon chips to enable high-throughput, low-cost production. The company generates revenue primarily through transactional sales of synthetic genes, oligo pools, and variant libraries, alongside a growing portfolio of Next-Generation Sequencing (NGS) target enrichment tools and biopharma discovery services. As of early 2026, the company has segmented its operations into DNA Synthesis, NGS Applications, and Biopharma Solutions, with a long-term R&D focus on DNA data storage. Twist positions itself as the market's high-volume, low-cost leader, competing directly with Integrated DNA Technologies (IDT), GenScript Biotech, and 10x Genomics by leveraging its 90% reduction in chemical usage to undercut legacy synthesis pricing while maintaining superior scalability. The company was co-founded in 2013 by a team of industry veterans, led by CEO Dr. Emily Leproust, who previously held a senior leadership role at Agilent Technologies and is a pioneer in high-density DNA synthesis. The executive team includes President and COO Dr. Patrick Finn, CFO Adam Laponis, and CTO Siyuan Chen, who oversees the technical evolution of the silicon platform. Twist's leadership is supported by a board featuring prominent figures such as Lead Independent Director Robert Chess and has historically secured backing from high-profile institutional investors including Fidelity Investments, Illumina, and Paladin Capital. This pedigree in both genomics and semiconductor engineering remains a core competitive advantage as the firm moves toward its stated goal of adjusted EBITDA breakeven by the end of fiscal 2026.